Volume 3, Issue 1 (Autumn 2011 -- 2011)                   BCN 2011, 3(1): 48-57 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Baluchnejadmojarad T, Roghani M, karimi N, kamran M. Varenicline Ameliorates Learning and Memory Deficits in Amyloid β(25–35) Rat Model of Alzheimer’s Disease. BCN. 2011; 3 (1) :48-57
URL: http://bcn.iums.ac.ir/article-1-206-en.html

Introduction: Alzheimer’s disease (AD) is a enfeeble neurodegenerative disorder characterized by increased β-amyloid (Aβ) deposition and neuronal dysfunction leading to impaired learning and recall. Among proposed risk factors, impaired cholinergic transmission is a main cause for incidence of disease.


In the present study, effects of the intracerebroventricularly administration of an agonist of nicotinic cholinergic receptors, varenicline(0.5 and 2 μg/μl), on learning and memory impairments induced by intrahippocampal Aβ(25–35) injection was assessed in rats.


The results showed that the intrahippocampal Aβ(25–35) injected rats exhibit lower spontaneous alternation score inY-maze tasks (p<0.05), impaired retention and recall capability in the passive avoidance test (p<0.05), and fewer correct choices (p<0.001) and more errors(p<0.001) in the RAM task. Varenicline, almost in both doses, significantly improved alternation score in Y-maze task (p<0.001), impaired retention and recall capability in the passive avoidance test (p<0.05), and correct choices in the RAM task (p<0.001).


This study indicates that varenicline pretreatment attenuates Aβ- induced impairment of short-term spatial memory in rats probably due to its agonist activity at nicotinic receptors.

Type of Study: Original | Subject: Clinical Neuroscience
Received: 2012/04/19 | Published: 2011/10/15

Add your comments about this article : Your username or Email:

© 2020 All Rights Reserved | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb